SpaXen

SpaXen is a South Korean biotechnology company focused on developing innovative antisense oligonucleotide (ASO) therapeutics for neurodegenerative diseases. The company leverages its proprietary S-GENT (Spatial Gene Expression Control Technology) platform, which enables the precise regulation of gene expression by targeting specific RNA sequences. SpaXen's research and development efforts are primarily directed toward high-unmet-need conditions such as Alzheimer's and Parkinson's diseases. By enhancing the tissue specificity and therapeutic index of RNA-based drugs, SpaXen aims to provide more effective treatments for complex central nervous system disorders. The company is currently advancing several pre-clinical programs designed to modulate key pathological proteins in the brain while overcoming traditional delivery challenges associated with RNA therapeutics.